Summary In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 ± 26 x 106 IU m2] and Cl esterase inhibitor (C1-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' treatment with standard (CD 66 ± 12 x 106 IU m-2) or escalating-dose (CD 99 ± 8 x 106 IU m-2) IL-2. IL-2-induced hypotension was equivalent and complement activation was less after IL-2 + C1-INH (C3a = 10.5 ± 3.2 nmol -l1) than following standard (14.1 ± 8.4 nmol l') or escalating-dose (18.3 ± 2.9 nmnol' 1) IL-2. This study demonstrates that Cl -INH administration during IL-2 treatment is safe and warrants further study to evaluate its ability to ameliorate IL-2-induced toxicity.
Although interleukin 2 (IL-2) has proved to be an effective therapy for some renal cell carcinoma and melanoma patients, its utility has been limited by toxicity. Dose-limiting toxicity consists of hypotension and damage to small blood vessels, leading to a capillary leak syndrome characterised by fluid retention and weight gain. The severity of the toxicity is proportional to the IL-2 dose administered. During IL-2 therapy the complement system becomes activated Moore et al., 1991; Vachino et al., 1991; Baars et al., 1992; Clayman et al., 1992) . This activation is dose dependent (Thijs et al., 1990; Baars et al., 1992) , occurs via several pathways including the classical route (Thijs et al., 1990; Moore et al., 1991; Vachino et al., 1991) , and correlates with the degree of hypotension induced (Baars et al., 1992) and parameters of capillary leakage (Thijs et al., 1990; Baars et al., 1992) . The classical route of complement activation is regulated by Cl esterase inhibitor (C1-INH). In a preliminary study the administration of human C1-INH to patients with septic shock appeared to be safe and was probably associated with attenuation of complement activation . In this pilot study we have investigated the feasibility of using C1-INH to ameliorate the hypotension induced by high-dose IL-2.
Patients and methods
Six patients (Table I) (Table I ) who had previously received IL-2 at escalating doses of 18-36 x 106 IU m-2 day-' also for 4 days (historical-control course). All IL-2 was given by a 15 min infusion. The experimental and historical-control courses were administered in the intensive care department, and both groups received parenteral nutrition. The self-control course was given in the high-care section of the Oncology Department but without parenteral nutrition.
Hypotension (systolic blood pressure >95 mmHg) was treated initially with plasma expanders and where necessary with dopamine or noradrenaline.
Blood samples for measurement of C1-INH and complement components were obtained and stored as previously described (Nuijens et al., 1989) . Total plasma C1-INH was measured with a nephelometer (Behring Werke Nephelometer Analyzer, Behring Werke) and expressed as a percentage of normal by reference to pooled plasma from normal blood donors (normal values 70-134%). Plasma C3a (levels >5 nmol 1-1 are elevated) was measured with a competitive radioimmunoassay (Hack et al., 1988) .
Results were expressed as means and standard deviations. Comparisons within and between groups were done by using a paired Student t-test. Proportions were compared by using Fisher's exact test. P-values <0.05 were considered statis- tically significant. Mean blood pressure was derived from the sum of one-third systolic blood pressure and two-thirds diastolic blood pressure. Changes in blood pressure between groups were analysed by using the percentages of the baseline values. The slope of linear trend in the measured variables plotted against the cumulative dose of IL-2 administered was determined with the linear regression technique.
Results
The cumulative IL-2 doses given during the experimental course (264 ± 26 x 106 IU m-2) were significantly higher than those during either the self-(66 ± 12 x 106 IU m2) or historical-(99 ± 8 x 106 IU m-2) control courses. Because the C1-INH plasma levels of the first patient did not exceed 152% after 24 h, C1-INH was given in doses of 1,000 U every 12 h instead of 500 U thereafter.
The mean blood pressure decreased from 94± 8 to 77 ± 14 mmHg during the experimental course. This fall was not significantly different from that seen during the selfcontrol course (98 ± 13 to 89 ± 10 mmHg) or the historicalcontrol course (89 ± 8 to 85 ± 8 mmHg). During the experimental course the decrease in mean blood pressure plotted against the administered IL-2 dose was less than that of the self-control course (slope of linear trend -0.08 vs -0.15) and similar to that observed during the historical-control course (slope of linear trend -0.08) (Figure la) . Vasopressors were administered during an equivalent number of patient days during the experimental and the historicala control courses (10/23 vs 6/10 respectively).
There was an equivalent gain in body weight during the experimental and the historical-control courses, + 5 + 2.6% vs + 3.6 ± 1.3%, both significantly greater than during the self-control course (weight change -0.2 ± 1.7%). This o difference was due to the greater fluid load from parenteral nutrition rather than a more severe capillary leak syndrome alone.
O°.
Baseline plasma C3a values were in the normal range and o did not differ significantly between courses. During the experimental and self-control courses C3a rose to a similar degree (10.5 ± 3.2 and 14.1 ± 8.4 nmol '-l at 96 h respectively) but was significantly lower than after the historical-control course (18.3 ± 2.9 nmol 1'). The increase in plasma C3a levels plotted against the administered IL-2 dose was less during the experimental course (slope of linear trend 0.02) than during b the self-control and historical-control courses (slope of linear trend 0.12 and 0.14) ( Figure Ib) .
During the administration of C1-INH no side-effects were observed. C1-INH administration caused a significant increase in the plasma levels of total C1-INH from 128 ± 28% to 166 ± 39% immediately before the start of the IL-2 infusion in the experimental course. Total C1-INH increased gradually thereafter to 195 ± 33% after 96 h. During the self-control course total C1-INH did not change significantly (148 ± 47 to 136 ± 19%). In the historical controls total Cl-INH remained at baseline levels during the first two treato ment days and thereafter it increased from 124 ± 16% to o 178 ± 17% at 96 h after the start of IL-2. Modulation of early mediators of IL-2 toxicity, such as tumour necrosis factor (TNF), can also result in reduced toxicity (Mier et al., 1990) . The dexamethasone used to achieve suppression of TNF release was, however, associated with undetectable NK activity in those patients and with the lack of objective regressions in another study (Vetto et al., 1987 
